Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefotaxime dosing regimens for SDD airway decontamination in ICU patients
NL-OMON33091Active, not recruiting
- Sponsor
- Haaglanden Medical Centre
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cefotaxime in airway colonization by potentially pathogenic microorganisms and pneumonia (2 arms), sponsored by Haaglanden Medical Centre. Primary endpoint: Airway colonization by potential pathogenic microorganisms after four days. Started Feb 2010; status: active, not recruiting.
02
Drugs
cefotaxime
03
Conditions
airway colonization by potentially pathogenic microorganismspneumonia
Beyond the preview
Go deeper on NL-OMON33091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33091.